Form 4: Kiniksa Pharmaceuticals CFO Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Mark Ragosa, CFO of Kiniksa Pharmaceuticals International, plc, sold 15,944 Class A Ordinary Shares on March 20, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- On March 20, 2025, Mark Ragosa, the Chief Financial Officer of Kiniksa Pharmaceuticals International, plc, executed a sale of 15,944 Class A Ordinary Shares.
- The sale was conducted under a pre-arranged 10b5-1 trading plan established on September 3, 2024.
- The shares were sold at an average price of $23.11, with individual transactions ranging from $23.10 to $23.185.
- Ragosa also acquired 15,944 shares at a price of $12.97.
- Following the reported transactions, Ragosa directly owns 23,382 Class A Ordinary Shares.
- Ragosa also holds options for 8,374 shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transactions.
Industry Context
This filing is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. The sale represents a small percentage of the company's total outstanding shares.
Comparison to Industry Standards
- Executive compensation packages often include stock options and grants, leading to periodic sales of shares.
- The use of 10b5-1 trading plans is a standard practice among publicly traded companies to ensure compliance with insider trading regulations.
- Comparing Ragosa's transactions to those of CFOs at similar-sized pharmaceutical companies would provide a better understanding of whether these sales are typical.
Stakeholder Impact
- The sale of shares by a company executive could be perceived negatively by some investors, potentially leading to a slight decrease in share price.
- However, the existence of a pre-arranged 10b5-1 plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| 09/03/2024 | Date of execution of the 10b5-1 plan by the reporting person. |
| 03/20/2025 | Date of the transaction (sale and acquisition of shares). |
| 03/24/2025 | Date of signature of the Form 4 filing. |
| 09/01/2031 | Expiration date of the share options. |
Keywords
Kiniksa Pharmaceuticals, Mark Ragosa, CFO, Class A Ordinary Shares, SEC Form 4, 10b5-1 plan, Insider Trading, Share Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.